By Market Intelligence Team

OPEN MINDS, The Behavioral Health & Social Service Industry Analyst Industry News By 2010, the smoking cessation and addiction treatment market will reach $2.3 billion in value, more than double its 2005 value of $1.1 billion. The key growth drivers will be health agencies’ worldwide interest in smoking cessation and the approximately 1.4 billion smokers worldwide. Pfizer’s Chantix smoking cessation treatment is projected to acquire the largest market share and displace Zyban as the smoking cessation treatment of choice. These projections are included in a . . .
Restricted Content

You must be a member to view this resource.

Log in | Sign up or learn more about membership options
OPEN MINDS, The Behavioral Health & Social Service Industry Analyst Industry News By 2010, the smoking cessation and addiction treatment market will reach $2.3 billion in value, more than double its 2005 value of $1.1 billion. The key growth drivers will be health agencies’ worldwide interest in smoking cessation and the approximately 1.4 billion smokers worldwide. Pfizer’s Chantix smoking cessation treatment is projected to acquire the largest market share and displace Zyban as the smoking cessation treatment of choice. These projections are included in a . . .
Restricted Content

You must be a member to view this resource.

Log in | Sign up or learn more about membership options

Login to access The OPEN MINDS Circle Library. Not a member? Create your free account now!